01:38 AM EDT, 10/12/2026 (MT Newswires) -- Ascelia Pharma's (ACE.ST) new drug application for Orviglance requires additional clinical evidence from a new clinical study, according to minutes from its type A meeting with the US Food and Drug Administration published Sunday. At the same time, the regulator noted the potential to generate clinical evidence through a prospective analysis of images from the phase 3 sparkle study using a different primary endpoint. The Swedish biotechnology company, which does not intend to conduct another clinical study of the drug, will mull over the most efficient course for it in the US.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.